Structural brain correlates of serum and epigenetic markers of inflammation in major depressive disorder by Green, Claire et al.
 
 
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Structural brain correlates of serum and epigenetic markers of
inflammation in major depressive disorder
Citation for published version:
Green, C, Shen, X, Stevenson, AJ, Conole, ELS, Harris, MA, Barbu, MC, Hawkins, EL, Adams, MJ, Hillary,
RF, Lawrie, SM, Evans, KL, Walker, RM, Morris, SW, Porteous, DJ, Wardlaw, JM, Douglas Steele, J,
Waiter, GD, Sandu, A, Campbell, A, Marioni, RE, Cox, SR, Cavanagh, J, Mcintosh, AM & Whalley, HC
2020, 'Structural brain correlates of serum and epigenetic markers of inflammation in major depressive
disorder', Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2020.11.024
Digital Object Identifier (DOI):
10.1016/j.bbi.2020.11.024
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Version created as part of publication process; publisher's layout; not normally made publicly available
Published In:
Brain, Behavior, and Immunity
Publisher Rights Statement:
This is the Journal pre-proof that has been peer reviewed and accepted for publication.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 03. Dec. 2020
Journal Pre-proofs
Structural brain correlates of serum and epigenetic markers of inflammation in
major depressive disorder
Claire Green, Xueyi Shen, Anna J. Stevenson, Eleanor L.S. Conole, Mathew
A. Harris, Miruna C. Barbu, Emma L. Hawkins, Mark J. Adams, Robert F.
Hillary, Stephen M. Lawrie, Kathryn L. Evans, Rosie M. Walker, Stewart W.
Morris, David J. Porteous, Joanna M. Wardlaw, J Douglas Steele, Gordon D.
Waiter, Anca-Larisa Sandu, Archie Campbell, Riccardo E. Marioni, Simon R.
Cox, Jonathan Cavanagh, Andrew M. McIntosh, Heather C. Whalley
PII: S0889-1591(20)32400-4
DOI: https://doi.org/10.1016/j.bbi.2020.11.024
Reference: YBRBI 4376
To appear in: Brain, Behavior, and Immunity
Received Date: 4 September 2020
Revised Date: 9 November 2020
Accepted Date: 17 November 2020
Please cite this article as: Green, C., Shen, X., Stevenson, A.J., Conole, E.L.S., Harris, M.A., Barbu, M.C.,
Hawkins, E.L., Adams, M.J., Hillary, R.F., Lawrie, S.M., Evans, K.L., Walker, R.M., Morris, S.W., Porteous,
D.J., Wardlaw, J.M., Douglas Steele, J., Waiter, G.D., Sandu, A-L., Campbell, A., Marioni, R.E., Cox, S.R.,
Cavanagh, J., McIntosh, A.M., Whalley, H.C., Structural brain correlates of serum and epigenetic markers of
inflammation in major depressive disorder, Brain, Behavior, and Immunity (2020), doi: https://doi.org/10.1016/
j.bbi.2020.11.024
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover
page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version
will undergo additional copyediting, typesetting and review before it is published in its final form, but we are
providing this version to give early visibility of the article. Please note that, during the production process, errors
may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
© 2020 Published by Elsevier Inc.
1
Structural brain correlates of serum and epigenetic markers of 
inflammation in major depressive disorder
Claire Green1*, Xueyi Shen1, Anna J. Stevenson2,3, Eleanor L.S. Conole2,4, Mathew A. 
Harris1, Miruna C. Barbu1, Emma L. Hawkins1,  Mark J. Adams1, Robert F. Hillary2,Stephen 
M. Lawrie1, Kathryn L. Evans2, Rosie M. Walker 2,6, Stewart W. Morris2, David J. 
Porteous2,5, Joanna M. Wardlaw3,5,6, J Douglas Steele7, Gordon D. Waiter8, Anca-Larisa 
Sandu8, Archie Campbell2, Riccardo E. Marioni2, Simon R. Cox4, Jonathan Cavanagh9,10, 
Andrew M. McIntosh1,2, Heather C. Whalley1
Affiliations:
1 Division of Psychiatry, University of Edinburgh, Edinburgh, UK
2 Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of 
Edinburgh, Edinburgh, UK
3 UK Dementia Research Institute, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK
4 Lothian Birth Cohorts group, University of Edinburgh, Edinburgh, UK
5 Centre for Cognitive Ageing and Cognitive Epidemiology, Department of Psychology, University of 
Edinburgh, Edinburgh, UK
6 Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
7 Division of Imaging Science and Technology, School of Medicine, University of Dundee, Dundee, United 
Kingdom
8Aberdeen Biomedical Imaging Centre, Institute of Medical Sciences, University of Aberdeen, Aberdeen, 
United Kingdom
9 Institute of Infection, Immunity & Inflammation, College of Medical and Veterinary Life Sciences, University 
of Glasgow, Glasgow, UK
10 Institute of Health and Wellbeing, College of Medical and Veterinary Life Sciences, University of Glasgow, 
Glasgow, UK
*Corresponding Author: 
Claire Green, Division of Psychiatry, University of Edinburgh, Kennedy Tower, Royal Edinburgh 
Hospital, Morningside Park, Edinburgh, EH10 5HF.
Email: claire.green@ed.ac.uk;  Telephone: +44 (0)131 537 6687
Abstract word count- 250, Main text word count- 4479
2
Abstract
Inflammatory processes are implicated in the aetiology of Major Depressive Disorder (MDD); 
however, the relationship between peripheral inflammation, brain structure and depression 
remains unclear, partly due to complexities around the use of acute/phasic inflammatory 
biomarkers. 
Here, we report the first large-scale study of both serological and methylomic signatures of 
CRP (considered to represent acute and chronic measures of inflammation respectively) and 
their associations with depression status/symptoms, and structural neuroimaging phenotypes  
(T1 and diffusion MRI) in a large community-based sample (Generation Scotland; NMDD 
cases=271, Ncontrols=609). 
Serum-CRP was associated with overall MDD severity, and specifically with current somatic 
symptoms- general interest (β= 0.145, PFDR = 6×10-4) and energy levels (β= 0.101, PFDR = 
0.027), along with reduced entorhinal cortex thickness (β= -0.095, PFDR = 0.037). DNAm CRP 
was significantly associated with reduced global grey matter/cortical volume and widespread 
reductions in integrity of 16/24 white matter tracts (with greatest regional effects in the external 
and internal capsules, βFA=- -0.12 to -0.14). In general, the methylation-based measures showed 
stronger associations with imaging metrics than serum-based CRP measures (βaverage = -0.15 
versus βaverage = 0.01 respectively). 
These findings provide evidence for central effects of peripheral inflammation from both 
serological and epigenetic markers of inflammation, including in brain regions previously 
implicated in depression. This suggests that these imaging measures may be involved in the 
relationship between peripheral inflammation and somatic/depressive symptoms. Notably, 
greater effects on brain morphology were seen for methylation-based rather than serum-based 
measures of inflammation, indicating the importance of such measures for future studies.
Keywords: Major Depressive Disorder; Depression; Inflammation; C-reactive Protein; CRP; 
Methylation; Brain Morphology; Brain Structure; White Matter Integrity; MRI
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1. Introduction
Major depressive disorder (MDD) is the most common mental health condition in the general 
population (Whiteford et al., 2013). It is a heritable disorder (Howard et al., 2019; Sullivan et 
al., 2000) that can be linked to a diminished functioning and quality of life, medical morbidity, 
and mortality (Marcus et al., 2012; Sinyor et al., 2016). Activation of the peripheral immune 
system has been consistently associated with MDD and is implicated in its pathogenesis 
(Bhattacharya et al., 2016; Dantzer et al., 2008; Haapakoski et al., 2015; Raison et al., 2013; 
Strawbridge et al., 2015). Evidence has shown that markers of inflammation are upregulated 
in peripheral and central nervous system tissue of individuals with depression compared to 
healthy controls, including increased concentrations of proinflammatory cytokines and 
immune mediators in cerebrospinal fluid  (Dowlati et al., 2010; Lindqvist et al., 2009; Liu et 
al., 2012; Pandey et al., 2012). Furthermore, a meta-analysis of randomised control trials 
(n=2,370) of pro-inflammatory cytokine inhibitors showed these treatments significantly 
improved depressive symptoms compared with placebo, indicating a potentially casual role of 
inflammation in MDD (Kappelmann et al., 2018). 
One of the most common approaches to assess peripheral inflammation is by measuring serum 
levels of C-reactive protein (CRP). CRP plays a key role in human inflammation and can 
provide a proxy estimate for inflammatory activity (Lowe, 2005). It is widely used in clinical 
practice as a marker of acute inflammation and is a candidate biomarker for investigating 
inflammatory processes in MDD (Osimo et al., 2019). Meta-analyses have shown that serum 
CRP levels are reliably elevated in MDD (Valkanova et al., 2013) and have been found to 
predict future development of depression as well as resistance to standard antidepressant 
therapies (Au et al., 2015; Chamberlain et al., 2019; Strawbridge et al., 2015).  
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One hypothesis is that peripheral inflammation contributes to depressive symptoms through 
effects on the brain. There is increasing evidence that peripheral inflammation has effects on 
the brain via humoral and neural routes subsequently impacting upon neural cell function, 
changes in functional/structural connectivity and behavioural changes including depressive 
symptoms (Brydon et al., 2008; Harrison et al., 2016, 2009; Savitz et al., 2015a, 2015b, 2013). 
However, at present there is little evidence of associations between elevated serum CRP in 
MDD and alterations in brain structure or morphology. One exception is the large imaging 
study by Opel and colleagues that reported significantly increased CRP levels in association 
with reduced grey matter volume in 514 patients with MDD compared to 359 healthy controls, 
however associations with white matter integrity were not investigated (Opel et al., 2019). 
Further, although serum CRP is viewed as a proxy measure of inflammatory activity, it can be 
influenced by a number of current state factors such as recent infections, injuries, body mass 
index (BMI), or chronic inflammatory conditions (Kathiresan et al., 2006). Cross-sectional 
serum measures may also not capture chronic low grade/sub-acute inflammation over time, 
which is considered important in MDD (Goldsmith et al., 2016; Haapakoski et al., 2015). 
We therefore investigated a methylation marker of chronic inflammation using a recent large 
epigenome wide association study (EWAS) of CRP (Ligthart et al., 2016). From the CpG sites 
identified, a methylation score for CRP (DNAm CRP) was created (Barker et al., 2018); the 
score has since been generated in participants of Generation Scotland and showed greater 
longitudinal stability compared to serological CRP (n=7,028)(Stevenson et al., 2020). Since 
this measure of inflammation may be less prone to the acute effects of cross-sectional measures 
of serum CRP described above, DNAm CRP may provide a more stable signature of chronic 
inflammatory states compared to cross-sectional serum CRP (Byun et al., 2012; Talens et al., 
2010). Indeed, methylation risk scores of other phenotypes including MDD itself have 
demonstrated discriminatory utility (Barbu et al., 2020). 
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Here we present findings from both serological measures of CRP and a novel methylomic 
approach to investigate the role of inflammation in MDD with a comprehensive range of 
structural brain phenotypes, including white matter microstructure (n=189 phenotypes). The 
current study examines a large community-based sample (n=880) to investigate (i) associations 
between serum CRP and DNAm CRP and MDD symptoms, (ii) associations between both 
CRP (serum CRP and DNAm CRP) measures and structural imaging phenotypes (TI and 
diffusion MRI) and (iii) interaction effects between both measures of CRP and MDD diagnosis 
to determine the differential relationship of these inflammatory markers and imaging 
associations in depression.
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2. Methods and Materials
2.1 Participants
The participants in this study were recruited as part of the ‘STratifying Resilience and 
Depression Longitudinally’ (STRADL) study (2015-2019) which re-contacted participants 
from the Generation Scotland: Scottish Family Health Study (GS) via post for further 
assessment of mental health, specifically depression. Full details of the STRADL cohort and 
GS protocol are published elsewhere (Habota et al., 2019; Navrady et al., 2018; Romaniuk et 
al., 2019; Rupprechter et al., 2020; Smith et al., 2013; Stolicyn et al., 2020). A total of 880 
unrelated participants were included in this study, 880 individuals had serum CRP and 
symptoms data, 796 individuals had both serum CRP and T1 neuroimaging data, and of these 
764 individuals also had diffusion MRI (DTI) data. In terms of DNAm CRP, 598 individuals 
had DNAm CRP and symptom data, 590 individuals had both DNAm CRP and T1 data and of 
these 565 also had DTI data (Table 1).
Ethical approval for STRADL was formally obtained from the NHS Tayside committee on 
research (reference 14/SS/0039), and all participants provided their written informed consent. 
2.2 Clinical Assessment
A full medical history was obtained and updated from previous GS baseline assessment (Smith 
et al., 2013) and any new diagnoses or medical episodes recorded at the imaging assessment. 
Health and lifestyle data were also collected, as were physical measurements such as height 
and weight, from which BMI was derived as a covariate of interest (Habota et al., 2019).  
Smoking status was collected from GS baseline assessments as were the number of smoking 
pack years- full details have been reported by Barbu and colleagues (Barbu et al., 2020).
Participants in STRADL completed a broad range of tests designed to assess depression 
incidence/severity. All participants were screened for a lifetime history of MDD. A research 
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version of the Structured Clinical Interview for DSM disorders (SCID) (First et al., 2002) was 
used to assess symptoms of mood disorder. Diagnostic criteria were based on the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV-TR). From this, participants were given 
a binary score of no history of depression (0) or lifetime episode of depression (1). Using this 
definition our study had 271 cases of lifetime depression and 609 controls (Table 1). No 
participants met criteria for lifetime bipolar disorder. The Quick Inventory of Depressive 
Symptomatology (QIDS)(John Rush et al., 1986), a 16-item questionnaire, was employed in 
order to assess the severity of current depressive symptoms at the time of assessment among 
study participants. From this, a total QIDS score was calculated as a measure of current 
depression severity for analyses purposes. Additional analyses looking at further clinical 
features of MDD and associations with serum CRP and DNAm CRP were also conducted and 
are provided in supplementary materials (Table S23).
2.3 C-reactive Protein Measurement (CRP)
To obtain serum CRP levels, venepuncture was employed using a butterfly needle kit. Blood 
was extracted into clot activator gel for serum separation. CRP samples were taken and sent to 
NHS laboratories (Ninewells Hospital/Aberdeen Royal Infirmary) for analysis. The low-
sensitivity assay utilized in CRP analyses possessed a detection threshold of 4 mg/L and CRP 
levels below the 4mg/L detection threshold were recorded as 0. For analyses purposes, CRP 
levels were stratified based on this threshold limit into clinically relevant groups: <4 mg/L 
(clinically normal) and ≥4 mg/L (clinically elevated) (Ridker, 2003). Blood samples were taken 
concurrently with imaging analyses and depression measures. 
2.4 DNAm CRP Score Calculation 
Blood samples used to generate the DNAm CRP score were collected at the Generation 
Scotland baseline appointment (between 2006 and 2011) and DNA methylation was profiled 
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using the Illumina Human-MethylationEPIC BeadChip in two different sets. Pre-processing 
and quality control steps for both sets of methylation data have previously been fully reported 
(Madden et al., 2020; Stevenson et al., 2020). 
Full details of the calculation of the DNAm CRP score in GS have been reported previously 
(Stevenson et al., 2020). Briefly, methylation beta values were extracted for 6 CpG sites shown 
to have the strongest evidence of a functional association with serum CRP levels as shown by 
Lighthart and colleagues (n = 8863 and 4111 of European and African ancestries, respectively) 
(Ligthart et al., 2016). One of the 7 CpG sites (cg06126421) in the original study was 
unavailable in the GS dataset and was therefore not included in the current analysis resulting 
in 6 CpG sites. The beta values for the six CpG sites associated with serum CRP were then 
multiplied by their respective regression weights and summed to generate a single score for 
each STRADL participant (Stevenson et al., 2020).  As all the EWAS regression weights were 
negative, a higher DNAm CRP score corresponds to a score closer to zero.
2.5 MRI Acquisition and Analyses
STRADL participants were scanned at two centres: the Ninewells Hospital in Dundee and at 
the Aberdeen Royal Infirmary in Aberdeen. Participants in Dundee were scanned using a 
Siemens 3T Prisma-FIT (Siemens Healthineers, Erlangen, Germany) with a 20-channel head 
and neck coil and a back-facing mirror (software version VE11, gradient with max amplitude 
80 mT/m and maximum slew rate 200 T/m/s). In Aberdeen, participants were imaged on a 3T 
Philips Achieva TX series MRI system (Philips Healthcare, Best, Netherlands) with a 32-
channel phased-array head coil with a back-facing mirror (software version 5.1.7; gradients 
with maximum amplitude 80 mT/m and maximum slew rate 100. Both study centres followed 
the same protocol including structural sequences (Habota et al., 2019). 3T MRI scans were 
anonymised at the time of acquisition and only the T1 and DTI data are utilized in this study.  
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Scanning site was included as a covariate in statistical analyses. Full details of the imaging 
sequences and parameters are provided in supplementary materials.
T1 structural measures were processed using FreeSurfer version 5.3 (Dale et al., 2002) to 
quantify the volumes of 14 subcortical structures as well as the volumes, surface area and 
thickness of 34 cortical regions per hemisphere according to the Desikan-Killany atlas 
(Desikan et al., 2006).  Full details of the Freesurfer Quality Control (QC) steps are provided 
in supplementary materials and have also been reported in full previously(Neilson et al., 2019). 
Measures of thickness, surface area and volume were derived for each of the 68 cortical 
regions. The volumes of 14 subcortical structures – left and right accumbens area, amygdala, 
caudate nucleus, hippocampus, pallidum, putamen and thalamus – were also extracted from 
FreeSurfer output. Global measures of cortical volume, surface area and thickness were also 
derived, as well as 5 summed lobar measures (frontal, parietal, temporal, occipital and 
cingulate; Table S1). The number of QC edits made per individual were recorded to use as a 
covariate in statistical analyses.
For DTI data, pre-processing and quality control was performed using standard tools available 
from FSL (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki). Tract Based Spatial Statistics (TBSS) was 
carried out according to the ‘The Enhancing NeuroImaging Genetics through Meta-Analysis’ 
(ENIGMA) Consortium DTI protocol (http://enigma.ini.usc.edu/protocols/dti-protocols/).  
Region of interest (ROI) extraction analyses were then performed also using ENIGMA 
protocols to extract fractional anisotropy (FA) and mean diffusivity (MD) measures  
(http://enigma.ini.usc.edu/protocols/dti-protocols/). White matter tracts were categorised using 
the Johns-Hopkins University DTI-based white matter atlas (Mori et al., 2007). This resulted 
in 5 unilateral tracts and 19 bilateral tracts, as well as an average measure, for FA and MD. 
This included ten association fibres, three commissural fibres, eight projection fibres and four 
thalamic radiations (Table S1).
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2.6 Statistical Analyses
Subcortical/Cortical Measures
For all cortical and subcortical measures, age, sex, BMI, imaging batch, number of image edits 
per individual, hemisphere, assessment centre and standardised intracranial volume (ICV) were 
set as covariates in mixed-effect linear models for both serum CRP and DNAm CRP analyses. 
Additionally, smoking status and pack years smoked were included in all DNAm CRP analyses 
given the effects of smoking on a range of methylation-based measures (Joehanes et al., 2016). 
For unilateral structures and global/lobar measures, a general linear model was applied as 
above. Hemisphere was controlled for as a within-subject variable in all bilateral structural 
neuroimaging phenotypes, using mixed-effect models.
White Matter Integrity
For DTI measures, age, sex, BMI and assessment centre were included as covariates for all 
analyses and methylation set/smoking variables were additionally included for DNAm CRP 
analyses. Global integrity was determined by applying principal component analysis (PCA) on 
the 24 tracts to extract a latent measure. Scores of the first un-rotated principal component of 
FA/MD were extracted and set as the dependent variable (proportion of variance explained by 
the first principal component is provided in Table S2). We then separately examined four 
subsets of white matter tract for which scores of the first un-rotated principal component were 
also extracted: (a) association fibres, (b) commissural fibres, (c) projection fibres and (d) 
thalamic radiations. The tracts included in the four subsets are provided in supplementary 
materials (Table S1). Finally, we examined each white matter tract individually. Mixed-effect 
linear models were used for the measures of bilateral white matter tracts correcting for 
hemisphere as a within-subject variable, consistent with above, while general linear models 
were used for the unilateral midline tracts.
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Statistical Models
All analyses were conducted using R (version 3.2.3) in a Linux environment. As GS is a family-
based study we randomly included one participant per family in order to have an unrelated 
sample. Randomisation was conducted in R using the ‘rnorm’ function to create a random seed 
variable for each participant and one individual per family with the highest random number 
was included in subsequent analyses, excluding all other family members. Linear mixed-effects 
models (function ‘lme’ in R package ‘nlme’) and general linear models (function ‘glm’ in R 
package ‘stats’) were used to investigate structural brain metrics (Shen et al., 2020, 2017). False 
Discovery Rate (FDR) multiple comparison correction was applied to all bilateral/unilateral 
structures, lobes and white matter tracts, referred to as PFDR in this report, using the ‘p.adjust’ 
function in R and all betas were standardised. FDR correction was also applied over each sub-
analysis. We investigated: (i) associations between serum CRP and DNAm CRP and 
depression symptoms, (ii) associations between both CRP measures and structural imaging 
phenotypes (T1 and DTI) and (iii) CRP × MDD interaction effects using both measures of CRP 
(serum and DNAm), and case/control MDD status. Further analyses controlling for concurrent 
smoking in serum CRP-MDD associations (Table S22) and controlling for days between 
methylation and serological/MRI appointments in DNAm CRP associations are also provided 
in supplementary materials (Supplementary Tables S24-28).
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3. Results
3.1 Demographics
Descriptive statistics of the key variables as well as sample numbers for each analysis in this 
study are presented in Table 1. Case-control MDD and QIDS associations on the structural 
imaging metrics across the full sample are also provided in supplementary materials (Table 
S16-S21). 
3.2 Associations between serum CRP and DNAm CRP with depression symptoms
Serum C-reactive Protein
There were no significant associations between serum CRP and case/control MDD status. 
However, increased serum CRP levels were significantly associated with increased depressive 
symptoms as measured by the total QIDS score (β= 0.073, PFDR = 0.033; Figure 1). For the 
separate QIDS items, increased serum CRP levels were significantly associated with decreased 
energy levels (β= 0.101, PFDR = 0.027) and decreased general interest (β= 0.145, PFDR = 6×10-
4). 
A further supplementary analysis controlling for smoking status in serum CRP associations 
with depression is presented in supplementary materials (Table S22). This sample had reduced 
power of 101 participants, however, effect sizes for the main findings remained similar, total 
QIDS (β= 0.06, PFDR = 0.07), with general interest remaining FDR significant after additional 
correction for smoking status (β= 0.1, PFDR = 0.02). 
DNAm CRP
There were no significant associations between the DNAm CRP score and MDD case/control 
status, or any of the measures of depression symptoms from the QIDS. A supplementary 
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analysis looking at further clinical features of MDD (age of onset, recurrence, QIDS severity) 
and associations with serum CRP and DNAm CRP were also null (Table S23).
3.3 Associations of serum C-reactive Protein and DNAm CRP and structural brain 
metrics
Serum C-reactive Protein
There were no significant associations between serum CRP status and any global or lobar brain 
summary measures. For individual regions however, we found elevated CRP status was 
significantly associated with reduced thickness of the entorhinal cortex (β= -0.095, PFDR = 
0.037; Figure 2). There were no significant associations between serum CRP status on any of 
the DTI measures, globally or regionally (Figure 3).
DNAm CRP
For DNAm CRP (n=577), we report significant associations between an increased DNAm CRP 
score and smaller global grey matter (β= -0.06, p= 0.02) and smaller global cortical volume 
(β= -0.1, p= 0.01; Figure 4). There were no FDR significant associations with any of the 
regional structural measures.
With regard to DTI measures (n=566), increased DNAm CRP scores were significantly 
associated with decreases in white matter microstructure, including negative associations with 
gFA (β= - 0.07, p =0.04), FA in the external capsule (β= -0.14, PFDR = 0.02) and the anterior 
limb of the internal capsule (ALIC; β= -0.12, PFDR = 0.048). 
There were also significant associations with MD values for projection fibres (β= 0.098, PFDR 
= 0.019) and thalamic radiations (β= 0.079, PFDR = 0.028). We also tested the effects of the 
DNAm CRP score for MD of individual tracts and found FDR significant effects for 16/24 
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white matter tracts (Figure 4; Table S9).  One of the largest effect sizes found for an individual 
tract was for the ALIC (β= 0.1, PFDR = 0.042).
Results for an additional analysis controlling for the time interval between methylation data 
collection and imaging/serological collection (Table S24-28) were largely similar to the above 
findings. Results remained the same for all global and FA findings, and 14/16 of the previous 
MD tract findings remained FDR significant, with the largest effect sizes in the same tracts (the 
corticospinal tract and inferior-fronto-occipital fasciculus were no longer FDR significant, both 
PFDR = 0.056).
3.4 Interaction effects between peripheral inflammation and depress on structural brain 
metrics
Lastly, we tested interaction effects between both peripheral markers of inflammation and 
case/control status and structural brain measures. There were no significant interaction effects 
between serum CRP or DNAm CRP with MDD case/control status on any of the brain metrics 
investigated (Table S10-S15).
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4. Discussion
Using data from a large community-based sample, we report associations between serological 
and methylomic markers of CRP with 189 structural neuroimaging phenotypes and their 
interaction effects with MDD diagnosis. We show that serological CRP exhibited significant 
associations with overall current MDD symptoms, in particular somatic symptoms, as 
measured by QIDS scores. In terms of brain morphology, serum CRP was associated with 
decreased thickness of the entorhinal cortex, whereas DNAm CRP was more robustly 
associated with widespread imaging features including decreased global cortical volume, grey 
matter and decreased white matter integrity, with the greatest loss of integrity in the external 
capsule and the ALIC (as indexed by decreased FA and increased MD). Neither serum CRP or 
DNAm CRP had significant interaction effects with MDD case/control status with brain 
structure, indicating these relationships are not specific to the presence of a formal lifetime 
clinical diagnosis.
We found that increased serum CRP levels were associated with increased depressive 
symptoms, particularly two somatic symptoms, general interest and energy levels, which is 
consistent with the existing literature. Previous studies of inflammation and depressive 
symptoms have also found that inflammatory markers are associated with 
somatic/neurovegetative symptoms of depression including fatigue, impaired sleep and 
activity, rather than psychological or cognitive symptoms (Chu et al., 2019; Duivis et al., 2013; 
Iob et al., 2020; Jokela et al., 2016; Köhler-Forsberg et al., 2017; White et al., 2017). These 
findings suggest that elevated serum CRP may be a reliable biomarker of somatic symptoms 
and provides further support for ‘sickness behaviour’ theories of depression (Dantzer et al., 
2008) where such features are thought to stem from inflammatory responses (Iob et al., 2020). 
This is relevant in the mechanistic treatment of MDD, whereby somatic symptoms could 
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potentially be alleviated by therapeutics that target the immune system/pro-inflammatory 
mechanisms.
Across the whole sample, we also report that higher serum CRP was associated with a thinner 
entorhinal cortex. This region has also been associated with CRP in previous research. A study 
by Bettcher and colleagues found CRP was associated with smaller left medial temporal lobe 
volumes, which included the entorhinal cortex, and found that those with detectable levels of 
CRP demonstrated poorer performance in cognitive tasks (Bettcher et al., 2012). This area has 
also been associated with the development of somatic symptoms in previous research (Wei et 
al., 2015) where the medial temporal lobe is thought to be involved in the emotional component 
of somatic complaints, consistent with our findings above (Phelps, 2006). Previous research on 
the effects of inflammation on the entorhinal cortex are primarily pre-clinical or in the context 
of Alzheimer’s disease (AD); however, chronic neuroinflammation is associated with neuronal 
loss and BBB leakage in this region and the entorhinal cortex may represent an area that is 
particularly vulnerable to the effects of inflammation (Hauss-Wegrzyniak et al., 2002; 
Montagne et al., 2020). The current findings therefore also indicate the potential importance of 
this region in the aetiology of somatic symptoms in MDD.
The most prominent findings in this study are the global and regional imaging associations 
with DNAm CRP. To our knowledge, there are no previous studies on the relationship between 
peripheral blood DNA methylation CRP scores and brain structure in the context of depression. 
We found that DNAm CRP scores had a greater number of associations with imaging traits, 
and with larger effect sizes compared to serum CRP. DNAm CRP scores were associated with 
several structural neuroimaging measures including reductions in global grey matter and global 
cortical volume. We also found that increased DNAm CRP scores were associated with 
widespread white matter changes including reductions in FA in the external capsule and ALIC 
and increases in MD for projection fibres and thalamic radiations. This is highly consistent 
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with regions implicated in previous imaging studies of MDD (van Velzen et al., 2019). The 
ALIC in particular, has been consistently implicated in MDD with a large body of evidence 
finding reduced white matter integrity in individuals with MDD (Jia et al., 2010; van Velzen 
et al., 2020; Zhang et al., 2013; Zhu et al., 2011). These results indicate that there may be a 
chronic inflammatory component to both global decreases in white matter integrity and to 
decreases regionally in the ALIC, as seen in MDD. Previous mendelian randomization studies 
have also shown that CRP is likely to be causally involved in the pathogenesis of MDD, and 
the alterations in brain structure we report here may represent a biologically plausible 
mechanism underlying the link between CRP and somatic/depressive symptoms (Khandaker 
et al., 2020).  With increased availability of genetic instruments for brain imaging measures, 
future research could directly test causal and mechanistic links between inflammation, 
structural brain alterations and MDD.
These findings could also be considered in the context of the ‘inflammaging’ theory of ageing 
and accelerated ageing models of MDD (Wolkowitz et al., 2010). Chronic low-grade 
inflammation has been shown to accelerate age-related neurodegenerative processes including 
reductions in cortical volume and white matter integrity (Franceschi and Campisi, 2014) (Zhao 
et al., 2019). Similarly, MDD is associated with increased brain atrophy and ageing-related 
disease and inflammation is thought to be a common biological mechanism between MDD and 
brain ageing (Franceschi and Campisi, 2014). We found that the DNAm score was associated 
with reductions in both cortical volume and white matter integrity, consistent with previous 
findings for both inflammation and MDD effects on brain structure, discussed above 
(Wersching et al., 2010). Several potential biological mechanisms have been proposed in 
linking immunological changes to affective neurobiology. MDD has been associated with 
immune cell senescence in particular, and a study by Diniz et al found that a senescence 
associated secretory phenotype was associated with MDD severity (Diniz et al., 2019). Future 
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research could examine the relationships between a broader range of inflammatory markers (eg 
IL-6, HPA-axis genes), MDD and measures of biological brain age to determine the 
involvement of inflammatory mechanisms in accelerated brain ageing, and specifically in 
individuals with MDD.
Our findings indicate utility in combining serological and methylomic markers of inflammation 
in the investigation of MDD. Methylation markers of other traits have proven useful in the 
prediction of MDD in previous studies, (Humphreys et al., 2019; Ryan et al., 2017) and future 
work could investigate these in the context of brain imaging measures to further understanding 
of the role of peripheral inflammation in MDD. Our study found differential associations with 
MDD depending on the inflammatory marker investigated. The acute serological measure of 
CRP was associated with depressive symptoms whereas the chronic methylation signature 
demonstrated widespread associations with reduced white matter integrity of the brain. This 
could be due to the differential acute/chronic nature of each of these inflammatory markers. 
Serum CRP is a marker of current active peripheral inflammation and this was associated with 
current depression symptoms, particularly somatic symptoms. However, DNAm based 
measures, which are considered to reflect more chronic exposure over time (Byun et al., 2012), 
were related to what would be expected to be slower changing neural features, but not currently 
active, potentially transient, symptoms. Longitudinal measures of depressive symptoms may 
therefore be a more powerful way to detect associations with these types of chronic 
methylation-based inflammatory measures. This should also be considered in the context of 
our relatively well, community-based sample, as discussed in limitations below. From this 
relatively well sample, we have ascertained that chronic inflammation is robustly associated 
with brain atrophy and white matter disturbances, however a longitudinal study with a larger 
sample size of moderate/severe cases would be able to discern if chronic inflammation leading 
to brain atrophy is associated with longitudinal measures of MDD to disentangle these 
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relationships further. Overall, these findings suggest a possible relationship between 
methylation markers of the immune system and neuroimaging traits and highlights the utility 
of methylomic profiles for investigating brain phenotypes.
This study has a number of strengths, in particular, the STRADL study is a large community-
based sample with in-depth phenotypic assessment and neuroimaging data (n=880 in the 
current study). Our study also benefits from the inclusion of methylation data which provided 
a long-term signature of chronic/low-level inflammation, overcoming issues with single 
timepoint CRP measurement which fluctuates in response to numerous factors and is prone to 
measurement error. We have also utilized a data-driven approach by not selecting 
neuroimaging regions of interest prior to analyses. This allowed an assessment of the effects 
of inflammation and depression on a wide range of structural neuroimaging measures.  
Limitations of this study included a small number of current MDD cases in comparison to the 
number of controls. As this study is a community-based sample, this indicates that the 
participants with MDD are relatively well in comparison to MDD cases who are hospitalised. 
The mean depression symptom score (total QIDS) in the lifetime MDD group was 7.1, 
indicating mild depression levels in this group. Therefore, we are potentially not capturing the 
effects of moderate to severe forms of MDD. However, community-based sampling results 
may be more generalizable to the population than those obtained in a clinic. Furthermore, 
although CRP is widely used clinically to determine peripheral inflammation, it is ultimately a 
proxy for inflammatory activity(Stevenson et al., 2020) and the detection threshold for CRP in 
this study was 4mg/L; values lower than this were recorded as 0. This could lead to missing 
biologically relevant interactions at lower levels of CRP. We also note that we did not separate 
out unipolar versus bipolar depression or investigate associations with anxiety symptoms 
because of limitations with sample size. Another limitation of the current study is that 
methylation data was collected at the GS baseline appointment. We note however that the 
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results of the supplementary analysis accounting for this time interval between methylation 
data collection and imaging assessments revealed a similar pattern of findings (see 
Supplementary Tables 24-28). Lastly, although our study has found associations between 
peripheral inflammatory markers and structural brain alterations, the study does not provide 
evidence for causal mechanistic pathways. 
In conclusion, we found that serum CRP was associated with depressive symptoms, in 
particular somatic symptoms, and with a reduction of entorhinal cortex thickness. This study 
also utilized a methylomic signature of C-reactive protein to capture chronic signatures of low-
level inflammation. Here we found significant widespread associations with several structural 
neuroimaging measures, in particular, differences in white matter integrity, including regions 
previously implicated in MDD such as the external capsule and ALIC. This study highlights 
the utility of using both serological and methylation markers in a multi-level approach to study 
brain imaging and psychiatric phenotypes. Furthermore, as peripheral inflammation was 
associated with both changes in brain morphology and depression symptoms, inflammation 
may represent an important and clinically relevant therapeutic target for depressive symptoms.
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Table 1: Participant Demographics 
 Variable Unit Total (Cases and Controls) Controls MDD Cases p-value
Agea Years (M, SD) 59.7 (9.6) 60.8 (9.3) 57.3 (9.7) <0.01
Sexb Females (n,%) 504 (57.3) 313 (51.4) 191 (70.5)  <0.01
BMIa Mean (SD) 28.2 (5.9) 27.6 (5.5) 29.6 (6.5)  <0.01
SCID Diagnosis n 880 609 271 -
Total QIDS scorea Mean (SD) 4.7 (3.7) 3.6 (2.3) 7.1 (5)  <0.01
<4mg/L (n) 714 507 207
Serum CRP statusb
≥4mg/L (n) 166 102 64
  0.02D
em
og
ra
ph
ic
s*
DNAm CRP scorea Mean (SD) -0.012(0.0008) -0.012(0.0008) -0.0119(0.0007)  <0.01
Serum CRP and Symptoms n 880 609 271 -
Serum CRP and T1 n 796 557 239 -
Serum CRP and DTI n 764 537 227 -
DNAm CRP and Symptoms n 598 402 196 -
DNAm CRP and T1 n 590 397 193 -n
/a
na
ly
se
s
DNAm CRP and DTI n 565 382 183 -
*Demographics calculated on 880 participants with serum CRP and symptoms data, a= Wilcoxon t-test, b= Chi squared test
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Figure 1:  Raincloud plot of associations between serum CRP status and total QIDS score
Figure 1: Raincloud plot of Serum CRP status associations with total QIDS scores. Serum 
CRP status 0 represents individuals with serum CRP <4mg/L and serum CRP status of 1 
represents individuals with a serum CRP level of 4mg/L or higher.
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Figure 2: Raincloud plot of associations between serum CRP status and entorhinal thickness
Figure 2: Raincloud plot of Serum CRP status associations with entorhinal thickness. Serum 
CRP status 0 represents individuals with serum CRP <4mg/L and serum CRP status of 1 
represents individuals with a serum CRP level of 4mg/L or higher.
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Figure 3: Associations between serum CRP and structural brain phenotypes 
Figure 3: The dotted line indicates the p value threshold 0.05. Each dot represents one 
structural brain phenotype.  Each colour represents one imaging modality. The diamonds 
represent phenotypes that are also significant after FDR correction. 
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Figure 4: Associations between DNAm CRP score and structural brain phenotypes
Figure 4: The dotted line indicates the p value threshold 0.05. Each dot represents one 
structural brain phenotype.  Each colour represents one imaging modality. The diamonds 
represent phenotypes that are also significant after FDR correction. 
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Structural brain correlates of serum and epigenetic markers of 
inflammation in major depressive disorder
Highlights:
  We report the first large-scale study of both serological and methylomic signatures of 
C-reactive protein (CRP) and their associations with depression status/symptoms, and 
189 structural neuroimaging phenotypes.
 Serological CRP was associated with overall depression severity, and specifically 
with current somatic symptoms and reduced entorhinal cortex thickness.
 The CRP methylomic signature was associated with widespread reductions in white 
matter integrity (as indexed by decreased fractional anisotropy and increased mean 
diffusivity).
 These findings provide evidence for central effects of peripheral inflammation from 
both serological and epigenetic markers of inflammation, including in brain regions 
previously implicated in depression.
